94 related articles for article (PubMed ID: 24743201)
1. [Effectiveness of skin icing for reducing pain associated with luteinizing hormone-releasing hormone agonist injection].
Nomura T; Tsunoda K; Ohta S; Doi K; Miyoshi K; Hasegawa Y; Mizutani M
Gan To Kagaku Ryoho; 2014 Feb; 41(2):221-4. PubMed ID: 24743201
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of pain reduction upon injecting goserelin acetate using an ice pack].
Ikeda K; Ogawa Y; Nagahara H; Xiang Z; Sakurai K; Fukuoka T; Tokunaga S; Nishiguchi Y
Gan To Kagaku Ryoho; 2010 Feb; 37(2):291-3. PubMed ID: 20154487
[TBL] [Abstract][Full Text] [Related]
3. [Ice application for reducing pain associated with goserelin acetate injection].
Ishii K; Nagata C; Koshizaki E; Nishiuchi S
Gan To Kagaku Ryoho; 2013 Oct; 40(10):1361-3. PubMed ID: 24105059
[TBL] [Abstract][Full Text] [Related]
4. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
[TBL] [Abstract][Full Text] [Related]
5. [Effect of local cooling at injection site of goserelin acetate for pain relief].
Nukui A; Morita T
Gan To Kagaku Ryoho; 2011 Jun; 38(6):967-72. PubMed ID: 21677488
[TBL] [Abstract][Full Text] [Related]
6. Epididymal sparing bilateral simple orchiectomy with epididymoplasty: preservation of esthetics and body image.
Issa MM; Lendvay TS; Bouet R; Young MR; Petros JA; Marshall FF
J Urol; 2005 Sep; 174(3):893-7. PubMed ID: 16093982
[TBL] [Abstract][Full Text] [Related]
7. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
8. [A case of a premenopausal woman with advanced breast cancer treated with aromatization inhibition in combination with luteinizing hormone-releasing hormone agonist].
Hisamatsu K; Iwamori S; Minami K; Tanabe K; Ota K; Akiyama H
Gan To Kagaku Ryoho; 1997 Aug; 24(10):1327-30. PubMed ID: 9279354
[TBL] [Abstract][Full Text] [Related]
9. [Skin reaction induced by subcutaneous injection of LH-RH analogue].
Segawa N; Nishida T; Hamada S; Azuma H; Katsuoka Y; Nozaki K; Tsuji M
Hinyokika Kiyo; 2007 Oct; 53(10):695-8. PubMed ID: 18018584
[TBL] [Abstract][Full Text] [Related]
10. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
11. [The effects of LH-RH agonist alone or with flutamide in the treatment of stage D2 prostate cancer].
Ito T; Aizawa T; Yamamoto S; Ohkubo Y; Tsujino S; Miki M
Hinyokika Kiyo; 1998 Jul; 44(7):477-80. PubMed ID: 9752601
[TBL] [Abstract][Full Text] [Related]
12. Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection.
Montgomery BS; Borwell JP; Higgins DM
Prostate Cancer Prostatic Dis; 2005; 8(1):66-8. PubMed ID: 15700050
[TBL] [Abstract][Full Text] [Related]
13. Fifteen-second skin icing using a frozen gel pack is effective for reducing goserelin injection pain.
Naya Y; Hagiwara N; Takeuchi I; Mori M; Inagaki A; Nakanouchi T; Mikami K
Urol Int; 2014; 93(2):202-6. PubMed ID: 24287721
[TBL] [Abstract][Full Text] [Related]
14. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
Curry EA; Sweeney CJ
J Urol; 2002 Jul; 168(1):193. PubMed ID: 12050525
[No Abstract] [Full Text] [Related]
15. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
Bong GW; Clarke HS; Hancock WC; Keane TE
Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
17. [Time to normalization of testosterone after withdrawal of long time LH-RH agonist therapy in prostate cancer].
Kaku H; Tsushima T; Nasu Y; Kumon H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():182-7. PubMed ID: 12599568
[No Abstract] [Full Text] [Related]
18. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
Urol Int; 2006; 77(2):135-8. PubMed ID: 16888418
[TBL] [Abstract][Full Text] [Related]
19. [Characteristics, effects, side effects of the LH-RH agonist].
Miyanaga N; Akaza H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():177-81. PubMed ID: 12599567
[No Abstract] [Full Text] [Related]
20. Triptorelin embonate: a 6-month formulation for prostate cancer.
Whelan P
Expert Opin Pharmacother; 2010 Dec; 11(17):2929-32. PubMed ID: 20969451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
